137
Views
47
CrossRef citations to date
0
Altmetric
Abstracts

NUCLEAR FACTOR KAPPA B INDUCTION IN AIRWAY EPITHELIUM INCREASES LUNG INFLAMMATION IN ALLERGEN-CHALLENGED MICE

, , , , &
Pages 883-895 | Received 25 Oct 2008, Accepted 05 May 2009, Published online: 08 Dec 2009

REFERENCES

  • Bureau F, Delhalle S, Bonizzi G, Fievez L, Dogne S, Kirschvink N, Vanderplasschen A, Merville MP, Bours V, Lekeux P: Mechanisms of persistent NF-kappa B activity in the bronchi of an animal model of asthma. J Immunol. 2000;165:5822–5830.
  • Gagliardo R, Chanez P, Mathieu M, Bruno A, Costanzo G, Gougat C, Vachier I, Bousquet J, Bonsignore G, Vignola AM: Persistent activation of nuclear factor-kappaB signaling pathway in severe uncontrolled asthma. Am J Respir Crit Care Med. 2003;168:1190–1198.
  • Lilly CM, Tateno H, Oguma T, Israel E, Sonna LA: Effects of allergen challenge on airway epithelial cell gene expression. Am J Respir Crit Care Med. 2005;171:579–586.
  • Poynter ME, Irvin CG, Janssen-Heininger YM: Rapid activation of nuclear factor-kappaB in airway epithelium in a murine model of allergic airway inflammation. Am J Pathol. 2002;160:1325–1334.
  • Birrell MA, Hardaker E, Wong S, McCluskie K, Catley M, De AJ, Newton R, Haj-Yahia S, Pun KT, Watts CJ, Shaw RJ, Savage TJ, Belvisi MG: Ikappa-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. Am J Respir Crit Care Med. 2005;172:962–971.
  • Catley MC, Chivers JE, Holden NS, Barnes PJ, Newton R: Validation of IKK beta as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKK beta to pulmonary epithelial cells. Br J Pharmacol. 2005;145:114–122.
  • Choi IW, Kim DK, Ko HM, Lee HK: Administration of antisense phosphorothioate oligonucleotide to the p65 subunit of NF-kappaB inhibits established asthmatic reaction in mice. Int Immunopharmacol. 2004;4:1817–1828.
  • Henderson WR, Jr., Chi EY, Teo JL, Nguyen C, Kahn M: A small molecule inhibitor of redox-regulated NF-kappa B and activator protein-1 transcription blocks allergic airway inflammation in a mouse asthma model. J Immunol. 2002;169:5294–5299.
  • Huang TJ, Adcock IM, Chung KF: A novel transcription factor inhibitor, SP100030, inhibits cytokine gene expression, but not airway eosinophilia or hyperresponsiveness in sensitized and allergen-exposed rat. Br J Pharmacol. 2001;134:1029–1036.
  • Jeong DW, Yoo MH, Kim TS, Kim JH, Kim IY: Protection of mice from allergen-induced asthma by selenite: prevention of eosinophil infiltration by inhibition of NF-kappa B activation. J Biol Chem. 2002;277:17871–17876.
  • Yang L, Cohn L, Zhang DH, Homer R, Ray A, Ray P: Essential role of nuclear factor kappaB in the induction of eosinophilia in allergic airway inflammation. J Exp Med. 1998;188:1739–1750.
  • Ziegelbauer K, Gantner F, Lukacs NW, Berlin A, Fuchikami K, Niki T, Sakai K, Inbe H, Takeshita K, Ishimori M, Komura H, Murata T, Lowinger T, Bacon KB: A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol. 2005;145:178–192.
  • Poynter ME, Cloots R, van WT, Butnor KJ, Vacek P, Taatjes DJ, Irvin CG, Janssen-Heininger YM: NF-kappa B activation in airways modulates allergic inflammation but not hyperresponsiveness. J Immunol. 2004;173:7003–7009.
  • Cheng DS, Han W, Chen SM, Sherrill TP, Chont M, Park GY, Sheller JR, Polosukhin VV, Christman JW, Yull FE, Blackwell TS: Airway epithelium controls lung inflammation and injury through the NF-kappa B pathway. J Immunol. 2007;178:6504–6513.
  • Peebles RS, Jr., Dworski R, Collins RD, Jarzecka K, Mitchell DB, Graham BS, Sheller JR: Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice. Am J Respir Crit Care Med. 2000;162(2 Pt 1):676–681.
  • Cho HY, Morgan DL, Bauer AK, Kleeberger SR: Signal transduction pathways of tumor necrosis factor–mediated lung injury induced by ozone in mice. Am J Respir Crit Care Med. 2007;175:829–839.
  • Holtzman MJ, Cunningham JH, Sheller JR, Irsigler GB, Nadel JA, Boushey HA: Effect of ozone on bronchial reactivity in atopic and nonatopic subjects. Am Rev Respir Dis. 1979;120:1059–1067.
  • Holtzman MJ, Fabbri LM, O’Byrne PM, Gold BD, Aizawa H, Walters EH, Alpert SE, Nadel JA: Importance of airway inflammation for hyperresponsiveness induced by ozone. Am Rev Respir Dis. 1983;127:686–690.
  • Kafoury RM, Hernandez JM, Lasky JA, Toscano WA, Jr., Friedman M: Activation of transcription factor IL-6 (NF-IL-6) and nuclear factor-kappaB (NF-kappaB) by lipid ozonation products is crucial to interleukin-8 gene expression in human airway epithelial cells. Environ Toxicol. 2007;22:159–168.
  • Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ: Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med. 1997;156(3 Pt 1):737–743.
  • Knott PG, Gater PR, Dunford PJ, Fuentes ME, Bertrand CP: Rapid up-regulation of CXC chemokines in the airways after Ag-specific CD4+ T cell activation. J Immunol. 2001;166:1233–1240.
  • McKinley L, Kim J, Bolgos GL, Siddiqui J, Remick DG: CXC chemokines modulate IgE secretion and pulmonary inflammation in a model of allergic asthma. Cytokine. 2005;32:178–185.
  • Simpson JL, Grissell TV, Douwes J, Scott RJ, Boyle MJ, Gibson PG: Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax. 2007;62:211–218.
  • Mattoli S, Marini M, Fasoli A: Expression of the potent inflammatory cytokines, GM-CSF, IL6, and IL8, in bronchial epithelial cells of asthmatic patients. Chest 1992;101(3 Suppl):27S–29S.
  • Tillie-Leblond I, Pugin J, Marquette CH, Lamblin C, Saulnier F, Brichet A, Wallaert B, Tonnel AB, Gosset P: Balance between proinflammatory cytokines and their inhibitors in bronchial lavage from patients with status asthmaticus. Am J Respir Crit Care Med. 1999;159:487–494.
  • Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, Chu HW: Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160:1001–1008.
  • Mariner JM, Lantz V, Waldmann TA, Azimi N: Human T cell lymphotropic virus type I Tax activates IL-15R alpha gene expression through an NF-kappa B site. J Immunol. 2001;166:2602– 2609.
  • Ruchatz H, Leung BP, Wei XQ, McInnes IB, Liew FY: Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J Immunol. 1998;160:5654–5660.
  • Ruckert R, Brandt K, Braun A, Hoymann HG, Herz U, Budagian V, Durkop H, Renz H, Bulfone-Paus S: Blocking IL-15 prevents the induction of allergen-specific T cells and allergic inflammation in vivo. J Immunol. 2005;174:5507–5515.
  • Akbari O, Dekruyff RH, Umetsu DT: Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol. 2001;2:725–731.
  • Oh JW, Seroogy CM, Meyer EH, Akbari O, Berry G, Fathman CG, Dekruyff RH, Umetsu DT: CD4 T-helper cells engineered to produce IL-10 prevent allergen-induced airway hyperreactivity and inflammation. J Allergy Clin Immunol. 2002;110:460–468.
  • Vissers JL, van Esch BC, Hofman GA, Kapsenberg ML, Weller FR, van Oosterhout AJ: Allergen immunotherapy induces a suppressive memory response mediated by IL-10 in a mouse asthma model. J Allergy Clin Immunol. 2004;113:1204–1210.
  • Xystrakis E, Kusumakar S, Boswell S, Peek E, Urry Z, Richards DF, Adikibi T, Pridgeon C, Dallman M, Loke TK, Robinson DS, Barrat FJ, O’Garra A, Lavender P, Lee TH, Corrigan C, Hawrylowicz CM: Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest. 2006;116:146–155.
  • Matsumoto K, Inoue H, Fukuyama S, Tsuda M, Ikegami T, Kibe A, Yoshiura Y, Komori M, Hamasaki N, Aizawa H, Nakanishi Y: Decrease of interleukin-10-producing T cells in the peripheral blood of severe unstable atopic asthmatics. Int Arch Allergy Immunol. 2004;134:295–302.
  • Poynter ME, Irvin CG, Janssen-Heininger YM: A prominent role for airway epithelial NF-kappa B activation in lipopolysaccharide-induced airway inflammation. J Immunol. 2003;170:6257–6265.
  • Kim YK, Oh SY, Jeon SG, Park HW, Lee SY, Chun EY, Bang B, Lee HS, Oh MH, Kim YS, Kim JH, Gho YS, Cho SH, Min KU, Kim YY, Zhu Z: Airway exposure levels of lipopolysaccharide determine type 1 versus type 2 experimental asthma. J Immunol. 2007;178:5375–5382.
  • Alexis NE, Lay JC, Almond M, Peden DB: Inhalation of low-dose endotoxin favors local T(H)2 response and primes airway phagocytes in vivo. J Allergy Clin Immunol. 2004;114:1325–1331.
  • Boehlecke B, Hazucha M, Alexis NE, Jacobs R, Reist P, Bromberg PA, Peden DB: Low-dose airborne endotoxin exposure enhances bronchial responsiveness to inhaled allergen in atopic asthmatics. J Allergy Clin Immunol. 2003;112:1241–1243.
  • Schroeder TH, Lee MM, Yacono PW, Cannon CL, Gerceker AA, Golan DE, Pier GB: CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation. Proc Natl Acad Sci USA. 2002;99:6907–6912.
  • Kuipers H, Hijdra D, De VV, Hammad H, Prins JB, Coyle AJ, Hoogsteden HC, Lambrecht BN: Lipopolysaccharide-induced suppression of airway Th2 responses does not require IL-12 production by dendritic cells. J Immunol. 2003;171:3645–3654.
  • Pantano C, Ather JL, Alcorn JF, Poynter ME, Brown AL, Guala AS, Beuschel SL, Allen GB, Whittaker LA, Bevelander M, Irvin CG, Janssen-Heininger YM: Nuclear factor-kappaB activation in airway epithelium induces inflammation and hyperresponsiveness. Am J Respir Crit Care Med. 2008;177:959–969.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.